Question 1

What is the difference between Praluent and Repatha®?

Accepted Answer

Praluent is a pharmaceutical product and is developed by Regeneron Pharmaceuticals. Repatha® is Repatha® (evolocumab) is a monoclonal antibody that binds to and inhibits PCSK9, allowing increased clearance of LDL cholesterol from the bloodstream. and is developed by Sejong General Hospital.

Question 2

What are Praluent and Repatha® used for?

Accepted Answer

Praluent: Atherosclerosis, Complex dyslipidemia, Familial hypercholesterolemia - heterozygous. Repatha®: Heterozygous familial hypercholesterolemia (HeFH), Homozygous familial hypercholesterolemia (HoFH), Established cardiovascular disease (atherosclerotic cardiovascular disease) in patients requiring additional LDL lowering.

Question 3

Are Praluent and Repatha® in the same drug class?

Accepted Answer

No — Praluent is an uncategorised drug and Repatha® is PCSK9 inhibitor (monoclonal antibody).

	Praluent	Repatha®
Generic name	Praluent	Repatha®
Sponsor	Regeneron Pharmaceuticals	Sejong General Hospital
Drug class	—	PCSK9 inhibitor (monoclonal antibody)
Molecular target	Proprotein convertase subtilisin/kexin type 9	PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9)
Modality	Small molecule	Small molecule
Phase	FDA-approved	FDA-approved
Therapeutic area	Metabolic	Cardiovascular

Praluent vs Repatha®

At a glance

Mechanism of action

Approved indications

Praluent

Repatha®

Common side effects

Praluent

Repatha®

Further reading

Praluent	—
Repatha®	Repatha® (evolocumab) is a monoclonal antibody that binds to and inhibits PCSK9, allowing increased clearance of LDL cholesterol from the bloodstream.